Priority 22 from the Liver Glycogen Storage Disease (International) PSP
|UNCERTAINTY: Which is the role and use of medium-chain triglycerides (MCT) in the management of different patients with liver Glycogen Storage Disease? (JLA PSP Priority 22)|
|JLA question ID||0090/22|
There is much debate in literature on the indication and effect of MCT treatment for patients which liver GSD. This question illustrates that more research is needed into the treatment effects.
For details of the evidence checked, please see the spreadsheet held on the JLA website.
|Health Research Classification System category||Metabolic and endocrine|
|Extra information provided by this PSP|
|Original uncertainty examples||Do MCT diets help cardiomyopathy in GSD 111 ~ Is there a role for MCT in the management of GSD1? ~ Does the addition of MCT help in treatment?|
|Submitted by||Patient, carer and healthcare professionals|
|PSP unique ID||0090|
|PSP name||International Glycogen Storage Disease PSP|
|Total number of uncertainties identified by this PSP||72 (To see a full list of all uncertainties identified, please see the detailed spreadsheet held on the JLA website)|
|Date of priority setting workshop||24 May 2019|